Wedbush Expects Reduced Earnings for Larimar Therapeutics

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Equities researchers at Wedbush cut their Q1 2025 earnings estimates for Larimar Therapeutics in a research note issued to investors on Monday, March 24th. Wedbush analyst L. Chico now expects that the company will earn ($0.39) per share for the quarter, down from their previous estimate of ($0.25). The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. Wedbush also issued estimates for Larimar Therapeutics’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.52) EPS, FY2026 earnings at ($1.73) EPS and FY2027 earnings at ($1.17) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.16).

Several other brokerages have also issued reports on LRMR. Truist Financial assumed coverage on Larimar Therapeutics in a research note on Wednesday, January 29th. They set a “buy” rating and a $18.00 price target for the company. Guggenheim restated a “buy” rating and issued a $26.00 target price on shares of Larimar Therapeutics in a research report on Tuesday. HC Wainwright increased their price target on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Robert W. Baird decreased their price target on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday. Eleven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $20.22.

Larimar Therapeutics Stock Performance

Shares of NASDAQ:LRMR opened at $2.31 on Wednesday. The firm has a market capitalization of $147.39 million, a PE ratio of -2.01 and a beta of 0.99. Larimar Therapeutics has a 52-week low of $2.22 and a 52-week high of $11.20. The firm has a fifty day moving average of $3.14 and a 200 day moving average of $5.20.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Fi3 FINANCIAL ADVISORS LLC boosted its position in Larimar Therapeutics by 16.7% during the 4th quarter. Fi3 FINANCIAL ADVISORS LLC now owns 23,798 shares of the company’s stock valued at $92,000 after buying an additional 3,411 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Larimar Therapeutics by 18.7% during the third quarter. JPMorgan Chase & Co. now owns 21,771 shares of the company’s stock worth $143,000 after purchasing an additional 3,425 shares during the period. Franklin Resources Inc. grew its stake in shares of Larimar Therapeutics by 21.9% in the third quarter. Franklin Resources Inc. now owns 19,723 shares of the company’s stock worth $143,000 after purchasing an additional 3,549 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in Larimar Therapeutics by 12.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 35,525 shares of the company’s stock valued at $137,000 after purchasing an additional 3,877 shares during the period. Finally, Bank of America Corp DE raised its position in Larimar Therapeutics by 8.1% during the 4th quarter. Bank of America Corp DE now owns 53,190 shares of the company’s stock valued at $206,000 after purchasing an additional 3,980 shares during the last quarter. 91.92% of the stock is owned by hedge funds and other institutional investors.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.